Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy.

To the Editor: There is controversy regarding whether patients with AML receiving initial reinduction therapy for relapse after a complete remission (CR) of less than 24 months should receive investigational single agents rather than proven therapies such as high-dose ara-C (HDAC)-containing